World's Most Advanced Treatment Guidance For Drug-Resistant Cancers
What
Encyclopedic multi-analyte tumor profiling to identify functional and molecular features of the tumor which then inform selection of personalized anti-cancer treatment regimens.
For Whom
Patients with advanced or difficult-to-treat cancers, especially where the cancer is not responding to treatments.
How
Tumor components including malignant cells, proteins, DNA and RNA are isolated from tumor tissue and/or blood, analyzed by molecular and functional assays to identify features associated with response (or lack of response) to anti-cancer agents. These findings are integrated to generate patient-specific treatment regimens.
Why
Exacta™'s comprehensive, multi-dimensional and in-depth analysis of the cancer provides a detailed insight into tumor mechanisms. Such information has been clinically proven to help inform selection of safe and efficacious treatment regimens in cancers that do not respond to standard treatments.
Advantages
- Clinically proven to inform the selection of safe and efficacious treatments.
- Includes assessment of all molecular biomarkers indicated in the National Comprehensive Cancer Network (NCCN) guidelines.
- Evaluates additional clinically relevant biomarkers.
- Chemo-response profiling of live tumor / tumor associated cells aids the accurate selection of chemotherapy drugs.
- Guides treatment selection in label compliant as well as off-label settings.
Explore
Explore
A Revolutionary Blood Test To Detect Cancer Early,
So That It Could Be Cured.
10 Medawar Road,
The Surrey Research Park, Guildford,
Surrey, GU2 7AE, United Kingdom
Lessingweg1,
Bayreuth 95447,
Germany
Ambad, Nashik,
Maharashtra – 422010
India
Important:
- This analytical investigation/test is CE-IVD marked and intended for use by licensed medical professionals. It is designed for professional use only and is not intended for direct-to-consumer or patient use without a prescription. Carefully review the associated risks, benefits, and limitations before use.
- For healthcare professionals in Great Britain, this test is CE-marked and intended solely for use by licensed medical professionals. All promotional materials are directed exclusively to healthcare professionals and are not intended for direct-to-consumer or patient use without prescription. The Datar Cancer Genetics clinical laboratory in Guildford, United Kingdom, is fully certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and accredited by the College of American Pathologists (CAP). Equipped with cutting-edge technology and advanced analytics, the laboratory is also registered with the Care Quality Commission (CQC) and holds UKAS accreditation (Medical Laboratory No. 22238), ensuring the highest standards in medical testing and diagnostics.
- For healthcare professionals in the European Economic Area (EEA), this CE-IVD-marked analytical investigation/test is intended solely for licensed medical professional use and not for direct-to-consumer or patient use without prescription. All claims of performance and safety are based on the company’s technical documentation and conform to relevant regulations.
- For healthcare professionals in the United States, this analytical investigation/test is offered by a CLIA-certified and CAP-accredited laboratory and validated in accordance with applicable regulatory guidelines. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Its use is restricted to prescription by licensed medical professionals and their professional review and is further subject to applicable federal and state laws.
- Exacta is a Laboratory Developed Test (LDT) performed at the Datar Cancer Genetics laboratory in the United Kingdom.
- Service availability and regulatory status may vary by region. Please refer to the region-specific information for further details.